InspireMD Reports Narrower Loss In Q2 As Revenue Rebounds On Procedural Recovery

  • InspireMD Inc NSPR has recorded a robust increase in second-quarter FY21 sales of $1.04 million, +231.6% Y/Y, slightly missing the consensus of $1.1 million.
  • The Company posted a narrower EPS loss of $(0.46) compared to $(2.93) a year ago, beating the consensus of $(0.63).
  • This increase was driven by a 276.0% increase in sales volume of CGuard EPS from $271,000 to $1.02 million as non-emergency cases began to return to normal levels compared to Q2 2020 when procedures with CGuard EPS were mostly postponed as hospitals shifted resources to COVID-19. 
  • This increase was partially offset by a decrease of 54.8% in sales of MGuard Prime EPS from $42,000 to $19,000, driven mainly by the preferences favoring drug-eluting stents.
  • NSPR posted a gross profit of $262,000, from a gross loss of $120,000.
  • Cash and cash equivalents were $41.4 million.
  • Price Action: NSPR shares closed at $3.96 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPenny StocksGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!